55.23
price down icon1.62%   -0.91
 
loading
Novo Nordisk Adr stock is traded at $55.23, with a volume of 15.47M. It is down -1.62% in the last 24 hours and up +16.96% over the past month. With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$56.14
Open:
$55.82
24h Volume:
15.47M
Relative Volume:
1.03
Market Cap:
$187.24B
Revenue:
$45.44B
Net Income/Loss:
$16.18B
P/E Ratio:
15.20
EPS:
3.634
Net Cash Flow:
$9.21B
1W Performance:
-2.18%
1M Performance:
+16.96%
6M Performance:
-39.21%
1Y Performance:
-57.80%
1-Day Range:
Value
$54.73
$56.08
1-Week Range:
Value
$54.73
$57.35
52-Week Range:
Value
$45.05
$138.22

Novo Nordisk Adr Stock (NVO) Company Profile

Name
Name
Novo Nordisk Adr
Name
Phone
-
Name
Address
-
Name
Employee
78,387
Name
Twitter
@novonordisk
Name
Next Earnings Date
2024-12-06
Name
Latest SEC Filings
Name
NVO's Discussions on Twitter

Compare NVO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
55.23 249.45B 45.44B 16.18B 9.21B 3.634
Drug Manufacturers - General icon
LLY
Lilly Eli Co
727.21 665.99B 53.26B 13.80B -50.20M 15.30
Drug Manufacturers - General icon
JNJ
Johnson Johnson
178.43 430.51B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
212.56 376.28B 58.33B 3.73B 18.24B 2.10
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
129.73 248.60B 53.40B 13.68B 16.89B 6.9231
Drug Manufacturers - General icon
MRK
Merck Co Inc
84.71 209.94B 63.43B 16.42B 14.72B 6.49

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-13-25 Upgrade BNP Paribas Exane Underperform → Neutral
Aug-05-25 Downgrade UBS Buy → Neutral
Jul-31-25 Downgrade HSBC Securities Buy → Hold
Jul-30-25 Downgrade Barclays Overweight → Equal Weight
Apr-17-25 Downgrade BMO Capital Markets Outperform → Market Perform
Mar-13-25 Upgrade Kepler Hold → Buy
Mar-03-25 Downgrade Stifel Buy → Hold
Feb-12-25 Initiated Morgan Stanley Equal-Weight
Jan-06-25 Upgrade Bernstein Underperform → Mkt Perform
May-30-24 Initiated Goldman Buy
Apr-12-24 Initiated BMO Capital Markets Outperform
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Neutral
Dec-01-23 Initiated Cantor Fitzgerald Overweight
Oct-02-23 Initiated Argus Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-15-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22 Downgrade UBS Neutral → Sell
Jun-27-22 Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22 Upgrade JP Morgan Neutral → Overweight
May-31-22 Upgrade Guggenheim Neutral → Buy
Apr-25-22 Upgrade Cowen Market Perform → Outperform
Apr-12-22 Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-16-22 Upgrade Deutsche Bank Hold → Buy
Jan-25-22 Downgrade Liberum Hold → Sell
Dec-20-21 Downgrade JP Morgan Overweight → Neutral
Dec-17-21 Downgrade Deutsche Bank Buy → Hold
Jan-20-21 Downgrade Credit Suisse Outperform → Neutral
Jan-15-21 Initiated Deutsche Bank Buy
Sep-29-20 Initiated Berenberg Hold
Jul-06-20 Downgrade BofA Securities Buy → Neutral
May-11-20 Downgrade UBS Buy → Neutral
May-04-20 Initiated Cowen Market Perform
Mar-16-20 Upgrade BofA/Merrill Neutral → Buy
Jan-03-20 Downgrade Guggenheim Buy → Neutral
Nov-18-19 Upgrade Barclays Equal Weight → Overweight
Sep-17-19 Upgrade Citigroup Neutral → Buy
Aug-30-19 Downgrade Jefferies Hold → Underperform
Jun-20-19 Downgrade Deutsche Bank Buy → Hold
Jun-11-19 Upgrade Barclays Underweight → Equal Weight
Apr-29-19 Upgrade Credit Suisse Neutral → Outperform
Jan-29-19 Initiated Exane BNP Paribas Outperform
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Dec-29-17 Upgrade JP Morgan Underweight → Neutral
Dec-06-17 Upgrade BofA/Merrill Neutral → Buy
Dec-01-17 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-25-17 Downgrade Exane BNP Paribas Outperform → Neutral
Sep-06-17 Upgrade BofA/Merrill Underperform → Neutral
View All

Novo Nordisk Adr Stock (NVO) Latest News

pulisher
Sep 05, 2025

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication - Benzinga

Sep 05, 2025
pulisher
Sep 03, 2025

ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 03, 2025
pulisher
Sep 03, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming DeadlinesNVO - cnhinews.com

Sep 03, 2025
pulisher
Aug 31, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Aug 31, 2025
pulisher
Aug 26, 2025

Novo Nordisk Slumps While Philips Shines In European ADRs - Finimize

Aug 26, 2025
pulisher
Aug 25, 2025

NVO’s Debt-to-Equity Ratio at 0.59: What It Means for Novo Nordisk ADR’s Future - investchronicle.com

Aug 25, 2025
pulisher
Aug 25, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.

Aug 25, 2025
pulisher
Aug 24, 2025

Hims & Hers (HIMS) Stock Lawsuits: Investors Urged to Act - GlobeNewswire Inc.

Aug 24, 2025
pulisher
Aug 22, 2025

Novo Nordisk A/S Class Action Lawsuit: Pomerantz Law Firm Reminds Investors of Upcoming Deadlines - AInvest

Aug 22, 2025
pulisher
Aug 20, 2025

HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.

Aug 20, 2025
pulisher
Aug 20, 2025

INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.

Aug 20, 2025
pulisher
Aug 20, 2025

Using data models to predict Novo Nordisk A s (b Shares) Adrhedged stock movementBuy Signal & Weekly Stock Performance Updates - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Reversal indicators forming on Novo Nordisk A s (b Shares) Adrhedged stockJuly 2025 Action & Daily Growth Stock Investment Tips - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Can momentum traders help lift Novo Nordisk A s (b Shares) Adrhedged2025 Stock Rankings & Long-Term Safe Investment Plans - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Is Novo Nordisk A s (b Shares) Adrhedged showing signs of accumulationJuly 2025 Institutional & Low Risk Entry Point Tips - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Is Novo Nordisk A s (b Shares) Adrhedged still worth holding after the dipTrade Risk Assessment & Consistent Growth Equity Picks - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Does Novo Nordisk A s (b Shares) Adrhedged fit your quant trading modelMarket Trend Summary & Detailed Earnings Play Alerts - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Is Novo Nordisk A s (b Shares) Adrhedged stock ready for a breakoutMarket Risk Report & Verified Short-Term Plans - Newser

Aug 20, 2025
pulisher
Aug 19, 2025

What moving averages say about Novo Nordisk A s (b Shares) Adrhedged2025 Top Gainers & Community Verified Swing Trade Signals - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

What’s next for Novo Nordisk A s (b Shares) Adrhedged stock priceEarnings Recap Report & Expert Approved Momentum Trade Ideas - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Earnings visualization tools for Novo Nordisk A s (b Shares) AdrhedgedChart Signals & Precise Entry and Exit Recommendations - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Using portfolio simulators with Novo Nordisk A s (b Shares) Adrhedged includedJuly 2025 Catalysts & Verified Momentum Stock Ideas - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Novo Nordisk shares rise 1.58% premarket after board member Christina Law's ADR purchase. - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - The Manila Times

Aug 19, 2025
pulisher
Aug 19, 2025

Novo Nordisk Board Member Christina Law Buys $0.8 Million in ADRs - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Novo Nordisk Board Member Christina Law Purchases ADRs Worth DKK 0.8 Million - MarketScreener

Aug 19, 2025
pulisher
Aug 19, 2025

Technical signs of recovery in Novo Nordisk A s (b Shares) AdrhedgedPortfolio Risk Report & Real-Time Stock Entry Alerts - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Novo Nordisk A s (b Shares) Adrhedged stock prediction for this weekJuly 2025 Final Week & Pattern Based Trade Signal System - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Glenn Jorgensen @Glennjdk: "𝐖𝐞 𝐡𝐚𝐝 𝐦𝐨𝐫𝐞 𝐍𝐨𝐯𝐨 𝐍𝐨𝐫𝐝𝐢𝐬𝐤..." - eToro

Aug 19, 2025
pulisher
Aug 19, 2025

Using data filters to optimize entry into Novo Nordisk A s (b Shares) Adrhedged2025 Top Decliners & Technical Entry and Exit Alerts - Newser

Aug 19, 2025

Novo Nordisk Adr Stock (NVO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general MRK
$84.71
price up icon 0.79%
$283.64
price up icon 1.26%
$115.05
price up icon 2.02%
drug_manufacturers_general PFE
$24.88
price up icon 1.39%
drug_manufacturers_general SNY
$46.50
price up icon 2.58%
Cap:     |  Volume (24h):